Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Haematological malignancies

206MO - Treatment patterns in patients with mantle cell lymphoma: Report of the Asia-Pacific multinational retrospective registry study


04 Dec 2022


Mini Oral session: Haematological malignancies


Cancer Registries

Tumour Site



Hyungwoo Cho


Annals of Oncology (2022) 33 (suppl_9): S1515-S1520. 10.1016/annonc/annonc1127


H. Cho1, D.H. Yoon1, D.J. Kim2, K. Kang3, J. Kwak4, S. Tan5, J. Lee6, S.Y. Oh7, Y.R. Do8, S.H. Jeong9, H.J. Kang10, Y. Koh11, H.J. Kim12, S. Kim13, J.H. Won14, T. Chen15, D.H. Yang16, N.S. Chin17, H. Eom18, W.S. Kim19

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Internal Medicine, Kosin Univeristy Gospel Hospital, 602-702 - Busan/KR
  • 3 Internal Medicine, Korea University Anam Hospital, 136 705 - Seoul/KR
  • 4 Internal Medicine, Chonbuk National University Hospital, 561-712 - Jeonju/KR
  • 5 Hematology, Hospital Ampang, 68000 - Ampang Jaya/MY
  • 6 Hemato-oncology, Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 7 Internal Medicine Department, Dong-A University College of Medicine, 602-812 - Busan/KR
  • 8 Medicine, Dongsan Medical center (DSMC) - Keimyung University School of Medicine, Daegu/KR
  • 9 Hematology-oncology, Ajou University School of Medicine, 443-380 - Suwon/KR
  • 10 Internal Medicine, Korea Cancer Center Hospital, Seoul/KR
  • 11 Internal Medicine, SNUH - Seoul National University Hospital, 03080 - Seoul/KR
  • 12 Internal Medicine, HUMC - Hallym University Sacred Heart Hospital (HUSHH), 14068 - Anyang/KR
  • 13 Internal Medicine, Soonchunhyang University Bucheon Hospital, 420-767 - Bucheon/KR
  • 14 Hematology-oncology, Soonchunhyang University Hospital Seoul, 140-743 - Seoul/KR
  • 15 Hematology-oncology, NCKUH - National Cheng Kung University Hospital, 704 - Tainan City/TW
  • 16 Hemato-oncology, Chonnam National University Hwasun Hospital, 519-763 - Hwasun/KR
  • 17 ., SJMC - Sime Darby Medical Centre Subang Jaya, 47500 - Subang Jaya/MY
  • 18 Center For Hematologic Malignancies, National Cancer Center Hospital, 410-769 - Goyang/KR
  • 19 Medicine, Samsung Medical Center (SMC), 06351 - Seoul/KR


Login to access the resources on OncologyPRO.

Abstract 206MO


To better define the clinical characteristics, treatment patterns, and survival outcomes of patients with mantle cell lymphoma (MCL), we conducted a multinational retrospective registry study for newly diagnosed patients with MCL.


Clinical and laboratory data were collected from newly diagnosed MCL patients between January 2008 and December 2017 from 16 hospitals in South Korea, two in Malaysia, and one in Taiwan.


A total of 191 patients with MCL were enrolled in this retrospective registry study. The median age was 66 years (range, 38–90), and majority of the patients had advanced stage disease (n = 150, 83.8%). The most frequently administered 1st line regimen was R-CHOP like regimen (n = 117, 61.3%), followed by cytarabine containing regimen (n = 41, 21.5%). There was a significant difference in the treatment pattern between young (age < 65, n = 90) versus elderly patients (age ≥ 65, n = 101). Higher proportion of elderly patients received R-CHOP like regimen as 1st line regimen compared with young patients (72.3% vs. 48.9%), while cytarabine containing regimen was more frequently administered in young patients (38.9% vs, 5.9%). The treatment response to 1st line regimens were available in 176 patients. The overall response rate (ORR) and the complete response (CR) rate among these patients were 94.9% (n = 167) and 52.3% (n = 92), respectively. A total of 106 patients were treated with 2nd line regimen. The most frequently administered 2nd line regimen was ibrutinib (n = 29, 27.4%) and cytarabine based regimen (n = 29, 27.4%), followed by BR (n = 12, 11.3%). The treatment response to 2nd line regimens were available in 89 patients, and the ORR and the CR rate among these patients were 74.2% (n = 66) and 38.2% (n = 34), respectively. Survival outcomes will be updated and presented at the ESMO Asia Congress 2022.


The current study offers an opportunity to better understand the treatment patterns of patients with MCL in the Asia-Pacific region. The most commonly used 1st line regimen was R-CHOP like regimen. Ibrutinib and cytarabine based regimen were the most frequently administered 2nd line regimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


The work was funded by a research grant from Janssen Pharmaceuticals Ltd.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.